A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation

Inclusion Criteria: * Written informed consent with the date of the patient must be obtained. * Patient between 18-70 years of age receiving the primary kidney. * Female patients must have a negative pregnancy test prior to the enrolment. * Female patients of child bearing potential must agree to practice effective birth control during the study. Exclusion Criteria: * Kidney re-transplantation patients or received an organ transplantation other than a kidney. * PRA\>10% in the previous 6 months. * Patient who need antibody induction therapy. * Patient with significant liver disease, defined as having continuously elevated \>2 times of SGPT and/or SGOT and/or total bilirubin levels during the past 28 days. * Patient with severe infection requiring treatment, and/or severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer. * Patient has any history of severe cardiovascular, respiratory disease; or history of malignancy. * Patient is HIV or HBsAg positive. * Patient is allergic to Prograf or macrolide antibiotics.